Morgan Stanley keeps an Overweight rating and $650 price target on Intuitive Surgical (ISRG) after its Q4 pre-announcement, saying the company had a strong finish to 2024 with systems placements that were well ahead of estimates. The company’s 2025 worldwide da Vinci procedures guide of 13%-16% also landed right where the firm believes buyside expectations were, with upside risk to that estimate given the 15% installed base growth in 2024 and utilization improvements, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ISRG:
- Early notable gainers among liquid option names on January 15th
- Intuitive Surgical reports preliminary Q4 revenue $2.41B, consensus $2.2B
- Intuitive Surgical price target raised to $655 from $650 at Bernstein
- LLY, ABT, or ISRG: Which “Strong Buy” Healthcare Stock Could Deliver the Best Returns in 2025?
- Intuitive Surgical Strengthens Leadership with Key Promotions
Questions or Comments about the article? Write to editor@tipranks.com